Associate Professor of Oncology, Associate Professor of Medicine, Johns Hopkins University School of Medicine
Oncology
Dr. Mark J. Levis, MD
|
|
Give Review
Mark J. Levis is an expert in the field of Oncology. He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Mark Levis is a published doctor and has 27 publications published. The lastest was: 'Genomic analysis of germline and somatic variants in familial myelodysplasia/acute myeloid leukemia.' Mark Levis accepts all Medicare patients.
Publications
- Genomic analysis of germline and somatic variants in familial myelodysplasia/Acute myeloid leukemia.
- Inhibition of c-Kit by tyrosine kinase inhibitors.
- Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloi...
- Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia.
- Phase I/II Trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with Acute myeloid leukemia and myelodysplastic syndrome.
- Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for Acute leukemias and myelodyspl...
- FLT3 Kinase Inhibitor TTT-3002 Overcomes Both Activating and Drug Resistance Mutations in FLT3 in Acute Myeloid Leukemia.
- Targeting FLT3 to treat Leukemia.
- The evolving role of FLT3 inhibitors in Acute myeloid leukemia: quizartinib and beyond.
- Is Targeted Therapy Feasible in Acute Myelogenous Leukemia?
- Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with Acute myeloid leukemia.
- Expression of putative targets of immunotherapy in Acute myeloid leukemia and healthy tissues.
- Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.
- Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extraCellular regulated kinase.
- Quizartinib in Acute myeloid leukemia.
- Phase I Study of Quizartinib Administered Daily to Patients With Relapsed or Refractory Acute Myeloid Leukemia Irrespective of FMS-Like Tyrosine Kinase 3-Internal Tand...
- Tandem Duplication PCR: An Ultrasensitive Assay for the Detection of Internal Tandem Duplications of the FLT3 Gene.
- Phase II study of azacytidine plus sorafenib in patients with Acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
- FLT3 inhibitors for Acute myeloid leukemia: a review of their efficacy and mechanisms of resistance.
- Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
- Phospho-specific Flow: Fixating on the Target.
- Targeting the Leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
- Active oral regimen for elderly adults with newly diagnosed Acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib...
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.
- Advances in treating Acute myeloid leukemia.
Schools
University of California At San Francisco
Johns Hopkins University School Med
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Carcinoma in Situ
- Central Nervous System Lymphoma
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
Johns Hopkins University
Hospital
-
Johns Hopkins Hospital
Drug Facts
| NPI NUMBER | 1578507976 | |
| NPPES Provider LastName | LEVIS | |
| NPPES Provider FirstName | MARK | |
| NPPES Provider ZIPCode | 212870005 | |
| NPPES Provider State | MD | |
| Specialty Description | Radiation Oncology | |
| Total Claim Count | 147.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1578507976 |
| Last Name Of The Provider | LEVIS |
| First Name Of The Provider | MARK |
| View All |
Similar Doctors
|
|
Dr. Helen Gharwan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carole B. Miller, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Madhu Chaudhry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley D. Walker, MD |
|
|
Dr. Stephen H. Glasser, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Evan J. Lipson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Saranya A. Chumsri, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Jennifer A. Kanakry, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ashraf Z. Badros, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nilofer S. Azad, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michele K. Evans, MD |
|
|
Dr. Phillip A. Dennis, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David S. Ettinger, MD |
|
|
Dr. William H. Matsui, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. James G. Herman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard Humphrey, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Heather A. Parsons, MD
This Doctor is OpenDoctor Recommended.
|